Arch Capital Group Ltd. (ACGL)vsDrugs Made In America Acquisition II Corp. Ordinary Shares (DMII)
ACGL
Arch Capital Group Ltd.
$96.09
-0.11%
FINANCIAL SERVICES · Cap: $33.47B
DMII
Drugs Made In America Acquisition II Corp. Ordinary Shares
$10.16
-0.07%
FINANCIAL SERVICES · Cap: $647.37M
Smart Verdict
WallStSmart Research — data-driven comparison
ACGL leads profitability with a 24.4% profit margin vs 0.0%. ACGL trades at a lower P/E of 7.7x. ACGL earns a higher WallStSmart Score of 67/100 (B-).
ACGL
Strong Buy67
out of 100
Grade: B-
DMII
Avoid32
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 24 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 26.6%
Generating 1.3B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Revenue declined 10.5%
Earnings declined 7.1%
Distress zone — elevated risk
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ACGL
The strongest argument for ACGL centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 24.4% and operating margin at 26.6%. PEG of 1.06 suggests the stock is reasonably priced for its growth.
Bull Case : DMII
The strongest argument for DMII centers on Debt/Equity.
Bear Case : ACGL
The primary concerns for ACGL are Revenue Growth, EPS Growth, Altman Z-Score.
Bear Case : DMII
The primary concerns for DMII are P/E Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
ACGL profiles as a declining stock while DMII is a value play — different risk/reward profiles.
DMII is growing revenue faster at 0.0% — sustainability is the question.
ACGL generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor INSURANCE - DIVERSIFIED industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ACGL scores higher overall (67/100 vs 32/100), backed by strong 24.4% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arch Capital Group Ltd.
FINANCIAL SERVICES · INSURANCE - DIVERSIFIED · USA
Arch Capital Group Ltd., offers insurance, reinsurance and mortgage products worldwide. The company is headquartered in Pembroke, Bermuda.
Drugs Made In America Acquisition II Corp. Ordinary Shares
FINANCIAL SERVICES · SHELL COMPANIES · USA
Drugs Made In America Acquisition II Corp. (DMII) is a special purpose acquisition company (SPAC) focused on identifying and merging with innovative players in the pharmaceuticals and biotechnology sectors, prioritizing advancements in domestic drug manufacturing. Leveraging a seasoned management team with considerable industry expertise, DMII aims to execute strategic transactions that respond to market dynamics and foster sustainable practices. The company's mission encompasses enhancing supply chain resilience and promoting U.S. healthcare self-sufficiency, ultimately driving long-term value creation for shareholders and contributing to the growth of the American pharmaceutical landscape.
Compare with Other INSURANCE - DIVERSIFIED Stocks
Want to dig deeper into these stocks?